ZYXI News and Press, Zynex Inc. From 11/13/19

This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...

Zynex, Inc. (ZYXI) Q3 2019 Results Conference Call October 29, 2019 04:15 PM ET Company Participants Thomas Sandgaard - Chief Executive Officer Dan Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Marc Wiesenberger - B. Rile...

Image source: The Motley Fool. Zynex, Inc   (NASDAQ: ZYXI) Q3 2019 Earnings Call Oct 29, 2019 , 4:15 p.m. ET Operator Continue reading

ENGLEWOOD, Colo. , Oct. 29, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, ...

Comparing IRadimed To Another Monopoly IRadimed ( IRMD ) is the only provider of non-magnetic MRI products. Revenue and earnings have been growing robustly. The company is on course to its fourth consecutive quarter of record revenue and improving margins, yet the stock price performance o...

On the surface, Zynex’s (NASDAQ: ZYXI ) model of selling electrical stimulation devices and supplies at high margins with technically little direct competition appears to be an attractive opportunity. However, the company’s revenues reveal a business model increasingly vulnera...

ENGLEWOOD, Colo. , Oct. 17, 2019 /PRNewswire/ --  Zynex, Inc.  (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagno...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

We bought the medical device company Zynex ( ZYXI ) for the SHU portfolio twice (in June, at $10.36 and $8.75 ) and we had great expectations for the stock that didn't pan out, at least not immediately: As you can see, at the end of June the stock sort of crashed, not because of any bad...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...